ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2377

Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2077

Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2040

Steroid Psychosis and Neuropsychiatric Symptoms induced by Corticosteroid Injection in Rheumatology Patients

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2006

Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2105

Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1775

Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM

(1770–1779) Cytokines & Cell Trafficking Poster

10:30AM-12:30PM: Abstract Number: 2190

Successful Implementation of an Innovative Rheumatology Curriculum for Internal Medicine Residents: Fellow-Initiated Rheumatology EDUcation Project (FIRED UP)

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 2192

Survey of Healthcare Providers’ Knowledge and Attitudes Toward the Management of Uncontrolled Gout

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 2365

Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2285

Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2056

Systematic Review: Nutritional Interventions in Muscle Diseases

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2130

Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1790

Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2165

Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study

(2159–2194) Professional Education Poster

10:30AM-10:45AM: Abstract Number: 1760

Targeting the Female-biased Factor VGLL3 in Cutaneous and Systemic Lupus

Abstracts: Systemic Lupus Erythematosus – Animal Models (1758–1763)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].